All In Biotech

NDA 208910 · Azurity

Firvanq Kit

Vancomycin Hydrochloride · Oral

Priority review

Last checked: Nov 20, 2026Latest source record: Feb 16, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Jan 26, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

501

123 Phase 3, 64 recruiting

FAERS reports

7,489

6,661 serious, 1,458 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 14, 2026.

Vancomycin hydrochloride is indicated for the treatment of Clostridium difficil e‑associated diarrhea in adults and pediatric patients less than 18 years of age. Vancomycin hydrochloride is also indicated for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin‑resistant strains) in adults and pediatric patients less than 18 years of age. Important Limitations of Use Parenteral administration of vancomycin is not effective for the above infections; therefore, vancomycin must be given orally for these infections. Orally administered vancomycin hydrochloride is not effective for treatment of other types of infections. To reduce the development of drug‑resistant bacteria and maintain the effectiveness of vancomycin hydrochloride and other antibacterial drugs, vancomycin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Vancomycin hydrochloride is a glycopeptide antibacterial indicated in adults and pediatric patients less than 18 years of age for the treatment of: ( 1 ) Clostridium difficile ‑associated diarrhea Enterocolitis caused by Staphylococcus aureus (including methicillin‑resistant strains) Important Limitations of Use: ( 1 ) ( 5.1 ) Orally administered vancomycin hydrochloride is not effective for treatment of other types of infections. To reduce the development of drug‑resistant bacteria and maintain the effectiveness of vancomycin hydrochloride and other antibacterial drugs,...

Mechanism: Vancomycin is an antibacterial drug [ see Microbiology ( 12.4 ) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 26, 2018 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LabelLetterReview
2 products under this application
  • FIRVANQ KIT · VANCOMYCIN HYDROCHLORIDE EQ 50MG BASE/ML · FOR SOLUTION, ORAL · Prescription · TE AA
  • FIRVANQ KIT · VANCOMYCIN HYDROCHLORIDE EQ 25MG BASE/ML · FOR SOLUTION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Vancomycin" as an intervention, any sponsor and status, largest first.

All 501 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective856
  • acute kidney injury499
  • off label use464
  • pyrexia437
  • rash309
  • drug reaction with eosinophilia and systemic symptoms300
  • drug hypersensitivity291
  • condition aggravated267
  • pneumonia266
  • diarrhoea263
  • sepsis253
  • hypotension226

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200461
200551
200682
2007150
2008270
200999
201091
2011106
2012152
2013196
2014154
2015265
2016160
2017180
2018271
2019452
2020429
2021641
2022921
2023929
2024790
2025671
2026367

Recalls

1 FDA enforcement reports for this application.

  • Aug 24, 2021 · Class I · Terminated

    Product Mix-up: Incorrect diluent component included in the kit.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,708 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.